HIV/AIDS

For over two decades, we stood by our motto, “None shall be denied” and have been committed to the cause of HIV/AIDS. In our crusade against the disease, we have developed over 15 single and combination medicines that revolutionized HIV therapy, not just in India but across the world. Our world class scientific resources and educational platforms help physicians across the world manage the disease effectively. Our fight against HIV/ AIDS has increased accessibility worldwide. And with our continued commitment to research and development the world can look forward to further progress in our fight against HIV/ AIDS.

In 2001, we introduced the world’s first ever recommended 3-in-1 fixed dose combination (Stavudine + Lamivudine + Nevirapine) to fight AIDS. It was made available at less than $1 per day compared to over $12,000 per patient per year prevailing in most countries throughout the world. It lifted the death sentence from millions across the developing world. We have also done pioneering work in paediatric HIV and addressed the needs of every kind of HIV patient, from pregnant mothers to babies and from children to adults. It’s not surprising that today around 1 million patients in the world are on our Antiretrovirals, and with regular therapy they can live for years and lead a near normal life.

#IamPositive – Bernie

“When I first found out I was HIV positive, my first thought was - will my children and grandchildren be condemned by people because of my status?” Bernadette Bailey shares her story about living with HIV.

Know your status. Own your status

#IamPositive – Wade

“When I first started my treatment with ARV drugs, I thought I would never be able to live my life the same way. But that wasn’t the case. I can do everything I thought I couldn’t.” Watch Wade’s story about how he’s living with HIV

Know your status. Own your status

#IamPositive - Sameshni

Sameshni was devastated. That one positive sign turned everything around her to negative and shattered her dreams. Least did she know that facing the fear head-on could help her evolve as a stronger, healthier and happier person. Today, she is an inspiration to many - scaling great heights in life and is at the peak of happiness - despite being HIV+. 

Know your status. Own your status

A commitment beyond compare

In the early 1990s, India witnessed an alarming increase in the number of AIDS cases. We launched Zidovudine, an antiretroviral at 1/10th of the price available in international markets. Subsequently Lamivudine and Stavudine were launched. Nevirapine was launched in 2000 and this completed the availability of triple therapy manufactured in India.

In 2001, we developed the world’s first 3-in-1 recommended fixed dose combination (Stavudine + Lamivudine + Nevirapine) to fight HIV/ AIDS. This amazing breakthrough overcame many challenges: it ensured adherence, lessened pill burden and it was affordable and available to all at less than a ‘Dollar a Day’. It was the first anti-AIDS cocktail that brought the cost of treatment down from $12,000 per patient per year to around $300. Enabling millions across the developing world access to life-saving therapy.

Cipla today has the world’s widest range of Antiretroviral products approved by WHO, US FDA. 25 of our Antiretrovirals are approved under PEPFAR and pre-qualified by WHO. Our antiretrovirals are supplied to more than 115 countries and various Ministries of Health worldwide, including the Government of India and international aid agencies.